Disease · HP_0012743
Abdominal obesity
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Abdominal obesity. Diseases, record HP_0012743. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012743
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Abdominal obesity
- Open Targets ID
- HP_0012743
- Other names
- Central obesity
- Highest stage of its drugs
- Phase 3, for 3 of its 16 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RIMONABANT | CHEMBL111 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TESAMORELIN | CHEMBL1237026 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TELMISARTAN | CHEMBL1017 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELAFIBRANOR | CHEMBL3707395 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALISKIREN | CHEMBL1639 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INULIN | CHEMBL1201646 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OMEGA-3 FATTY ACIDS | CHEMBL4298065 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| SITAGLIPTIN | CHEMBL1422 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets106
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 2 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 2 | https://conductscience.org/library/genes/762 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4697 | Drugs and targets |
1 to 10 of 106
See all 106 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00608023 | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Phase 3 | 263 | 2014-01-15 | Lipodystrophy, HIV Infections | TESAMORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT00498433 | Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension | Phase 2 | 46 | 2013-10-24 | Hypertension, Abdominal Obesity | ALISKIREN, AMLODIPINE | Its record names the disease | ClinicalTrials.gov |
| NCT00365794 | Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men | Phase 2 | 22 | 2019-08-26 | Aging, Obesity, Insulin Resistance, Hypogonadism | TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00124332 | STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study) | Phase 3 | 839 | Coronary Atherosclerosis | RIMONABANT | Its record names the disease | ClinicalTrials.gov | |
| NCT04477590 | Interactions of Medicine and Exercise With Meal Timing | Not applicable | 160 | Metabolic Syndrome, Protection Against, Exercise Training, Metformin, Statins, Angiotensin-Converting-Enzyme Inhibitor, Fasting, Intermittent, Angiotensin Hypertension | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00147264 | Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial | Phase 3 | 120 | Metabolic Syndrome X | TELMISARTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT03630588 | Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity | Phase 2 | 120 | Obesity, Abdominal | INULIN, OMEGA-3 FATTY ACIDS | Its record names the disease | ClinicalTrials.gov | |
| NCT01271751 | Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity | Phase 2 | 96 | Atherogenic Dyslipidaemia, Abdominal Obesity | ELAFIBRANOR | Its record names the disease | ClinicalTrials.gov | |
| NCT00231608 | A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity | Phase 2 | 68 | Obesity | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00408148 | High Density Lipoprotein Turnover | Phase 3 | 64 | Obesity | RIMONABANT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 25392748 | RESULT | 1 | PubMed |
| 18387931 | RESULT | 1 | PubMed |
| 38015017 | DERIVED | 1 | PubMed |
| 35643872 | DERIVED | 1 | PubMed |
| 29540575 | DERIVED | 1 | PubMed |
| 28832410 | DERIVED | 1 | PubMed |
| 28752209 | DERIVED | 1 | PubMed |
| 25077901 | DERIVED | 1 | PubMed |
| 23731019 | DERIVED | 1 | PubMed |
| 23715754 | DERIVED | 1 | PubMed |
1 to 10 of 16
See all 16 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012743
GET https://conductscience.org/api/diseases/v1/HP_0012743/targets?page=2